Most academics want their work to have an impact, and one route to achieving this is by commercializing their findings. By partnering with an existing company to bring a product to market or by establishing a new spin-out enterprise, scholars can develop technologies, products and solutions that revolutionize whole sectors, whether in health care, construction or farming and more. But this is far from an easy or simple process, requiring tenacity, adaptability, collaboration and high-level problem-solving.

For this week’s podcast, we speak to two people with extensive experience in what it takes to commercialize research and become an academic entrepreneur.

Mairi Gibbs is CEO of Oxford University Innovation, the university’s technology-transfer unit, where she has worked since 2002. With extensive practical experience in partnership management, formation of spin-out companies, licensing and patent portfolio management, she explains the initial steps to commercialization, what investors look for and what can be done at an institutional level to support more spin-out activity.

Andrew Hammond is co-founder and head of R&D at Biocentis, an Imperial College London spin-out founded in 2022. With a background in molecular biology, Andrew’s 10-year academic career at both Imperial and Johns Hopkins University involved advancing gene editing technology for use in insects. This led to the development of gene drive technology designed for use on malaria mosquitoes and the later development of Biocentis.

For more advice and insight on this topic, read our spotlight guide on how to work well with industry

This episode is sponsored by Elsevier.

Listen to this podcast on Spotify, Apple podcasts or Google podcasts.

Found In

Share This Article